36 results about "Intestinal villus" patented technology

The invention discloses an application of a pyrrosia lingua aqueous extract in preparation of a medicine for preventing and treating radioactive intestinal injury. Radioactive intestinal injury is a common complication of ionizing radiation, and has main pathological characteristics of intestinal mucosal barrier destruction, excessive release of inflammatory factors, increase of oxidative stress level and hematopoiesis and immune function inhibition. At present, no effective and safe prevention and treatment medicine is available. It is found for the first time that the pyrrosia lingua aqueous extract can inhibit expression (IL-6, TNF-alpha and IL-1beta) of inflammatory factors of radiation-induced MODE-K cells and relieve the oxidative stress level (malondialdehyde (MDA) is reduced, and the content of superoxide dismutase (SOD) and glutathione (GSH) is increased). In animal experiments, the pyrrosia lingua aqueous extract can reduce the levels of TNF-alpha and IL-1beta inflammatory factors in serum of irradiated mice and improve oxidative stress disorders such as MDA increase, SOD and GSH decrease and the like; the reduction of leukocytes and lymphocytes is relieved; the length of intestinal villus is promoted and recovered; the proportion of Ki67 positive cells in a crypt region is increased, so that the regeneration capacity of intestinal epithelial cells is enhanced. The pyrrosia lingua aqueous extract disclosed by the invention provides an experimental basis and an application prospect for developing a novel medicine for preventing and treating the radioactive intestinal injury.

The application provides application of PAI-1 protein in detection and treatment of NEC patients and FNEC patients. The inventor of the application, in combination with years of experience and a large amount of research screening, obtains a biomarker capable of quickly assisting in diagnosis of NEC patients and identifying FNEC patients and Non-FNEC patients, and the biomarker is PAI-1 protein. The PAI-1 protein can be used for auxiliary diagnosis of NEC patients and early screening of FNEC patients, and FNEC patients are identified in time, so that intervention measures are taken in time, and mortality is reduced. Moreover, inhibition of expression of the PAI-1 protein can effectively relieve intestinal villus injury of a NEC model animal, and significantly reduce mortality. Therefore, the PAI-1 protein can be used as a potential target for treating NEC patients, and an agent for inhibiting expression of the PAI-1 protein can be used as a potential drug for treating NEC patients.

Cryptosporidium parvum is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Disclosed herein are inhibitors against the enzymatic activity of recombinant CpLDH protein that were identified. The inhibitors were tested for anti-Cryptosporidium effect using in vitro infection assays of HCT-8 cells monolayers. Compounds NSC158011 and NSC10447 were identified to inhibit the proliferation of intracellular C. parvum in vitro, with IC50 values of 14.88 and 72.65 μM, respectively. At doses tolerable in mice, both NSC158011 and NSC10447 significantly reduced the shedding of C. parvum oocysts in infected immunocompromised mice's feces and prevented intestinal villous atrophy as well as mucosal erosion due to C. parvum. These findings have unveiled anti-Cryptosporidium drug candidates that can be explored further for the development of therapeutic agents against C. parvum infections.

This invention relates to the field of feed additive technology, specifically to a feed additive that promotes digestion and absorption and its preparation process. The preparation process of a feed additive that promotes digestion and absorption includes: preparing antioxidant-modified chicken fat; preparing an extract; preparing a composite oil phase; and preparing the feed additive. In this invention, the extract of Shenqu (a type of fermented wheat) can directly compensate for insufficient endogenous enzyme secretion in laying hens, rapidly decomposing starch in feed and chicken fat in plant proteins, laying the foundation for subsequent absorption. The extract of Zhishi (a type of immature bitter orange) accelerates gastrointestinal motility and digesta emptying, while also promoting bile and pancreatic juice secretion, further improving the digestibility and utilization rate of fat-soluble components in laying hens. The extract of pine pollen can repair the intestinal mucosa, increase intestinal villus height, increase the nutrient absorption area, and regulate the intestinal microecology, reducing nutrient loss and intestinal stress. The combined use of these three ingredients synergistically promotes the digestive and absorptive capacity of laying hens.

The application discloses a kind of for radiation intestinal injury treatment composition and its application, it is related to medical technical field.The composition includes the following components: aesculetin, fraxinol, fraxin and baicalein.The composition of the application can reduce intestinal villus injury by regulating the NF-κB pathway and Caspase-9 / 3 pathway of intestinal epithelial cells, reduce the infiltration of intestinal inflammatory cells, reduce intestinal cell apoptosis, to relieve intestinal injury, and then multi-component, multi-pathway jointly play the efficacy of treating radiation intestinal injury.The application solves the problem that there is no effective drug for treating radiation intestinal injury in the prior art.

The invention discloses application of oxidized berberine and neohesperidin in improving intestinal health of broiler chickens, and belongs to the technical field of feed additives. Research finds that oxidized berberine and neohesperidin can increase the intestinal villus height, crypt depth and goblet cell number of broiler chickens and improve intestinal health; the slaughter indexes such as daily weight gain and feed intake can be improved, the feed-weight ratio is reduced, and the slaughter indexes such as carcass weight and semi-eviscerating weight are increased; meanwhile, the serum immune factor and antioxidant index level is improved, the safety is high, and no obvious toxicity exists; and the two components are combined for use, so that a synergistic interaction effect is also achieved. The invention provides a new raw material resource for improving the intestinal health of the broiler chicken and improving the production performance and economic value of the broiler chicken.

This invention discloses a strain of *Bacillus belyceae* with broad-spectrum antibacterial activity and its application in the prevention and treatment of necrotic enteritis in poultry. The *Bacillus belyceae* strain provided by this invention (… Bacillus from Velez The genome of strain GDG25CB056 is approximately 3.91 Mb in size, contains no virulence factors, and is rich in gene clusters encoding non-ribosomal peptides and polyketide synthases. Studies have confirmed that this strain exhibits significant growth advantages, strong tolerance to high temperatures, gastric acid, and bile salts, which facilitates intestinal colonization. It can produce siderophores and various enzymes, and has overcome the technical bottleneck of a narrow antibacterial spectrum, possessing broad-spectrum antibacterial activity, especially strong specific antagonistic activity against Clostridium perfringens. In vivo experiments have shown that this strain can significantly reduce the Clostridium perfringens load in the cecum of chicks with necrotizing enterocolitis, alleviate intestinal congestion and swelling, repair damaged intestinal villi, and enhance mucosal barrier function, providing a safe and efficient strain resource for the prevention and treatment of bacterial enteric diseases.

The invention discloses application of indole-3-acetaldehyde and salt thereof in a product for repairing animal intestinal injury, relates to the technical field of animal intestinal injury repairing, and aims to improve animal intestinal injury induced by vomitoxin. Animal experiments prove that after being treated by a product containing indole-3-acetaldehyde, the vomitoxin-induced intestinal injury degree can be remarkably reduced, the activity of intestinal stem cells can be remarkably improved, the villus height and permeability in intestines can be improved, proliferation and differentiation of the intestinal stem cells can be promoted, and the proliferation level of intestinal epithelial cells can be improved. A new thought can be provided for research and development of products for repairing the vomitoxin-induced intestinal injury, and a new nutrition regulation and control means can be developed for treating the vomitoxin-induced intestinal injury.

The application belongs to the technical field of organ chip models, and specifically discloses a liver-intestine chip model and a method for evaluating the influence of oligosaccharides on the liver by using the same. The liver-intestine chip model comprises a multilayer microfluidic structure, the main body material of the multilayer microfluidic structure is modified polydimethylsiloxane, the multilayer microfluidic structure comprises an intestinal microcavity, a liver microcavity and a microchannel connecting the two, the intestinal microcavity is inoculated with intestinal epithelial cells, the liver microcavity is inoculated with liver cells, the bottom of the liver microcavity is provided with a window array, the corner of the liver microcavity is provided with a groove, the bottom of the intestinal microcavity is integrated with an elastic membrane, the elastic membrane is communicated with an external air pressure driving system, and the upper surface of the elastic membrane is etched with a microstructure similar to small intestinal villi. By using the above liver-intestine chip model and the method for evaluating the influence of oligosaccharides on the liver by using the same, the liver-intestine organ chip model can simulate the microenvironment of the intestinal-liver axis in vivo, and provides a more real and reliable platform for studying the influence of oligosaccharides on the liver.

The invention discloses application of dryopteris fragrans polysaccharide in treatment of chronic lead poisoning, and belongs to the technical field of biology. The invention aims at solving the technical blank of application of dryopteris fragrans polysaccharide in chronic lead poisoning and solving the technical problems of complicated operation, low polysaccharide retention rate and low polysaccharide purity of a polysaccharide extraction and purification method in the prior art. According to the method for extracting and purifying the dryopteris fragrans polysaccharide, pigments and residual protein in the dryopteris fragrans polysaccharide can be effectively removed, the effect of reducing the deproteinization treatment frequency is achieved, the decolorization rate reaches 78.76%, the polysaccharide retention rate is high, and the method can be used for industrially producing the dryopteris fragrans polysaccharide. The dryopteris fragrans acidic polysaccharide obtained through the extraction and purification method can be applied to treatment of chronic lead poisoning, so that the purpose of reducing growth delay, liver and kidney injury and intestinal villus lesion caused by chronic lead poisoning is achieved.

The invention provides a plant lactobacillus MLPCO23 resistant to PEDV (porcine epidemic diarrhea virus) infection and application of the plant lactobacillus MLPCO23, and belongs to the technical field of microorganisms. The preservation number of the plant lactobacillus MLPCO23 is CCTCC (China Center for Type Culture Collection) NO: M 20252370. The plant lactobacillus MLPCO23 can be colonized in intestinal tracts, has a remarkable PEDV (porcine epidemic diarrhea virus) resisting effect, and can be used for improving the PEDV infection resisting capability of piglets and relieving clinical symptoms caused by PEDV infection. The plant lactobacillus MLPCO23 can repair intestinal villi and close connection structures, increase the number of goblet cells and maintain the steady state of intestinal barriers. The plant lactobacillus MLPCO23 serving as intestinal probiotics provides a new intervention target and a prevention and control strategy for PEDV infection, and also provides a new thought and a new clue for clarification of the effect and mechanism of Min pig flora for regulating intestinal mucosa microecology and resisting PEDV infection.

The invention provides application of ergothioneine in improving growth of large yellow croakers in a wintering period, improving liver oxidation resistance and enriching intestinal flora, and belongs to the technical field of aquaculture. According to the method, 25 mg / kg and 50 mg / kg of ergothioneine are added into feed for the larimichthys crocea juvenile fish in the wintering period for feeding, and results show that the ergothioneine can remarkably improve the weight gain rate, the specific growth rate and the muscle and whole fish crude fat content of the larimichthys crocea juvenile fish; the activity of CAT, T-SOD and GSH-Px in the liver of a test group is remarkably improved, and the content of MDA is remarkably reduced; in addition, the ergothioneine can improve the intestinal villus height of the larimichthys crocea juvenile fish in the wintering period and improve the abundance of intestinal flora, the abundance of harmful bacteria is reduced, and the abundance of beneficial bacteria is increased. The invention proves that the ergothioneine can promote the growth of the larimichthys crocea juvenile fish in the wintering period, enhance the oxidation resistance and improve the intestinal health, and can be used as a green feed additive for the larimichthys crocea in the wintering period.

The invention relates to lactobacillus amylovorans and an application thereof in intestinal diseases, the lactobacillus amylovorans (LA) is named as lactobacillus amylovorans QC1H, is preserved in China Center for Type Culture Collection on March 28, 2023, and has a preservation number of CCTCC NO: M2023427, the lactobacillus amylovorans and / or a fermentation product thereof can significantly improve the ratio of mouse intestinal villus length to crypt depth, and the lactobacillus amylovorans and / or the fermentation product thereof can significantly improve the intestinal villus length and crypt depth of mice. The compound has the advantages of reducing mouse ileum enteritis factor expression, improving ileum tight junction protein expression and reducing intestinal permeability, and has important application significance and value in preparation of a therapeutic agent for preventing and treating enteritis caused by aflatoxin B1 (AFB1).

The invention discloses enterococcus faecium for promoting intestinal tissue repair of aquatic animals and application of the enterococcus faecium, and relates to the technical field of aquaculture, the strain is named as GCE-2, the Latin name is Enterococcus faecium, the strain is preserved in the China General Microbiological Culture Collection Center on January 7, 2026, and the preservation number is CGMCC NO.37319. The invention further discloses a preparation method of the enterococcus faecium capable of promoting intestinal tissue repair of the aquatic animals and application of the enterococcus faecium capable of promoting the intestinal tissue repair of the aquatic animals. The enterococcus faecium GCE-2 provided by the invention can efficiently promote the repair of intestinal tissues of aquatic animals, has relatively strong intestinal colonization ability and good environmental adaptability, and can directly promote the regeneration of intestinal villus and the repair of epithelial cell injury, quickly relieve the pathological symptoms of intestinal tracts and remarkably improve the repair efficiency of the intestinal tissues.

The invention relates to application of a CXCL14 recombinant protein in preparation of a medicine for preventing or treating radiation enteritis, and belongs to the technical field of biomedicine. Excessive inflammation is inhibited by regulating chemotaxis and pro-inflammatory polarization of key immune cells such as macrophages. The CXCL14 recombinant protein directly acts on intestinal epithelial cells and crypt stem cells to promote intestinal villus repair and crypt regeneration, so that the intestinal barrier is structurally recovered. The specific value of intestinal villus length / crypt depth is remarkably increased, and it is proved that the CXCL14 recombinant protein can achieve functional healing instead of symptom relieving.

The invention provides application of astaxanthin in preparation of medicines for preventing and treating intestinal dysfunction and intestinal flora imbalance related to severe acute pancreatitis or repairing intestinal mucosal barrier. In-vivo experiments prove that the astaxanthin can significantly improve SAP-induced intestinal barrier injury, reduce the activity of serum diamine oxidase (DAO), repair a jejunum villus structure and up-regulate the expression of tight junction proteins (ZO-1, Occludin and Claudin); the mechanism relates to inhibition of local inflammatory response and oxidative stress, and specific correction of intestinal flora disorder, including recovery of proportion balance of phylum firmicalis and bacteroides, and improvement of abundance of beneficial bacteria such as lactobacillus murine and ruminococcus; the invention provides a new strategy for clinical treatment of SAP complicated with intestinal failure.

This invention belongs to the field of microbiology technology, and specifically relates to the application of a strain of *Lactobacillus suis* HL1 derived from wild boars in Xinjiang and its feed additives. Lactobacillus saerimneri HL1, with accession number CGMCC No. 34386. This invention relates to *Lactobacillus suis* HL1, which exhibits good tolerance, strong antioxidant capacity, and effective antibacterial properties. It is sensitive to multiple antibiotics and promotes growth and development, enhancing intestinal villi growth, increasing nutrient absorption, and improving coat luster. This application isolates a potentially beneficial *Lactobacillus* strain with low or no drug resistance from wild boars in Xinjiang and evaluates its in vivo safety, laying the foundation for animal feed additives.

The application discloses a pig breed disease resistance breeding screening method based on taurine cholate metabolic markers, and belongs to the technical field of animal breeding. The application effectively screens the breeding pigs with stronger intestinal barrier function by establishing a breeding standard based on the intestinal barrier function difference, especially taking the taurine cholate level as a key index, and improves the health level and production benefit of pigs. Compared with the prior art, the ileum villus height to crypt depth ratio of the breeding pig is increased by 25.3%, the mRNA relative expression amount of ZO-1 and other tight junction proteins is increased by 32.7%, the SIgA and IgG levels are increased by 38.5%, the health level of the pig is significantly improved, and the production benefit is increased by 15.6%.

The invention belongs to the technical field of organ chip models, and particularly discloses a liver and intestine chip model and a method for evaluating the influence of oligosaccharide on the liver through the liver and intestine chip model. The liver and intestine chip model comprises a multi-layer micro-fluidic structure, and the main body material of the multi-layer micro-fluidic structure is modified polydimethylsiloxane; the multi-layer micro-fluidic structure comprises an intestinal microcavity, a liver microcavity and a micro-channel connecting the intestinal microcavity and the liver microcavity, the intestinal microcavity is connected with similar intestinal cells, the liver microcavity is connected with similar liver cells, a window hole array is arranged at the bottom of the liver microcavity, grooves are formed in the corners of the liver microcavity, an elastic film is integrated at the bottom of the intestinal microcavity, and the elastic film is connected with the micro-channel. The elastic film is communicated with an external pneumatic driving system, and a micro-structure similar to intestinal villi is etched on the upper surface of the elastic film. By the adoption of the liver and intestine chip model and the method for evaluating the influence of the oligosaccharide on the liver through the liver and intestine chip model, the liver and intestine organ chip model can simulate the microenvironment of the intestine-liver axis in the body, and a more real and reliable platform is provided for studying the influence of the oligosaccharide on the liver.

The application discloses a kind of bionic small intestine villus aerogel and its preparation method and application, the aerogel includes the aerogel framework with layered structure, and bionic villus structure is grafted on layered structure;Including by mass fraction: carbon source 1-1.5 parts, crosslinking agent 1.5-2.5 parts, catalyst 0.2-0.5 parts, phytic acid-polyethyleneimine ligand 0.5-1 part.It is prepared as follows: polyethyleneimine ligand aqueous solution is adjusted to be acidic, phytic acid aqueous solution is added, and white precipitate is generated by stirring, and ligand is obtained by washing, freeze-drying, and powder is obtained by grinding;Carbon source is dissolved, and crosslinking agent, catalyst are sequentially added, and gel precursor is formed by stirring, and ligand powder is added after stirring, and directional freeze-drying is carried out, and it is prepared.The application grafts biological-based electrolyte ligand into aerogel system with layered structure by in-situ polymerization method, constructs bionic small intestine villus type composite aerogel, enhances flame-retardant and heat-insulating performance, and significantly improves antibacterial performance.

The application discloses application of caprylic capric glycerides in preparation of products for relieving or inhibiting intestinal cell iron death of piglets. It is found that the caprylic capric glycerides have a regulating effect on intestinal cell iron death of piglets, and feeding piglets with products containing the caprylic capric glycerides can relieve or inhibit intestinal epithelial cell iron death of piglets, protect the intestinal morphology and function of piglets, and relieve or inhibit intestinal cell iron death of piglets induced by Escherichia coli K88. Feeding piglets with feed products containing the caprylic capric glycerides can positively regulate the jejunal villus height and the ratio of the jejunal villus height to the crypt depth of piglets, the ultrastructure of the jejunal of piglets, the protein expression amount of the tight junction protein ZO-1 of the jejunal of piglets, the contents of 4-HNE, GPX4, MDA and GSH in the jejunal of piglets, and the protein expression amount of the iron death signal path related factors (FTH1, GPX4, SLC3A2 and TFR1) of the jejunal of piglets, and can positively and comprehensively protect the intestinal health of piglets.

The application discloses application of ergothioneine in preparation of products for improving growth performance, immunity, antioxidant capacity or intestinal health of fish, and belongs to the technical field of biotechnology.It is found by experiments that ergothioneine can promote growth of large yellow croaker larvae and improve muscle quality; ergothioneine can enhance immunity and antioxidant defense capacity and improve liver and intestinal health; meanwhile, ergothioneine can improve liver tissue vacuolization and intestinal villus structure and improve intestinal digestive enzyme activity; ergothioneine can regulate intestinal flora structure and intestinal metabolism; and ergothioneine can also induce systematic remodeling of liver metabolism group and transcription group.In summary, ergothioneine is a natural functional feed additive with wide application prospect, which can synergistically promote fish growth, health and quality improvement by enhancing antioxidant defense, improving liver metabolic homeostasis, maintaining intestinal structure and optimizing intestinal microecology.

The present invention relates to the technical field of weaned piglet feeds, and particularly discloses a weaned piglet growth performance and intestinal health improving feed, which comprises the following raw materials by weight: 50-65 parts of corn, 15-25 parts of soybean meal, 2-5 parts of fish meal, 3-8 parts of whey powder, 1-3 parts of soybean oil, 0.5-1.5 parts of stone powder, 0.5-1.5 parts of calcium hydrophosphate, 0.2-0.5 part of edible salt, and 0.1-0.4 part of lysine. The feed is prepared from the following raw materials in parts by weight: 0.05 to 0.15 part of methionine, 0.05 to 0.15 part of threonine, 0.5 to 1.5 parts of premix, 0.05 to 0.10 part of sodium butyrate, 0.01 to 0.03 part of bacillus subtilis and 0.005 to 0.015 part of origanum oil. The feed for improving the growth performance and intestinal health of the weaned piglets can improve the antioxidant capacity in serum of the weaned piglets, promote the development of intestinal villus, maintain the integrity of intestinal barriers, improve the immune function of the intestinal tracts and increase the amino acid transport of the intestinal tracts.

The invention discloses an artificial intestinal villus bionic peristalsis experimental model driven by a variable magnetic field, and belongs to the technical field of bionic in-vitro models. The model comprises a flexible substrate and an artificial magnetic intestinal villus array constructed on the surface of the flexible substrate. A plurality of annular electrified coils are arranged, the coils sequentially and continuously sweep over the outer wall of the long cylindrical small intestine model in a surrounding mode, then space-time changing magnetic field distribution is formed, the villus array is driven to generate periodic collaborative movement with phase differences, the directional wriggling function of the digestive tract is simulated, and the conveying and mixing process of food and medicine in the digestive tract is reproduced. By adjusting the current intensity, the frequency and the operation speed of the coil, accurate control over the direction, the amplitude and the frequency of villus movement can be achieved, and therefore the intestinal tract dynamic characteristics under different physiological or pathological conditions are simulated. The model disclosed by the invention can be matched with a fluid channel, a permeable membrane or cell culture for use, and is used for in-vitro research on a drug release and transportation mechanism, food digestion kinetics, an intestinal disease mechanism and evaluation of related medical preparations and instruments.

The application discloses a lactoferrin-prepared drug for preventing and treating mycotoxin poisoning and an application thereof. Through in-vivo (intestinal tract) research on mice, vomitoxin is added in the diet of the mice to simulate the mice eating feed containing mycotoxin, and the mice are given intragastrically a lactoferrin solution containing a fixed concentration, so that the expression of inflammatory factors caused by vomitoxin can be reduced, and the expression of jejunal tight junction protein can be enhanced, thereby relieving the damage of vomitoxin to intestinal function. In addition, the lactoferrin can also regulate the colon microbiota of the vomitoxin-treated mice and improve intestinal microbial metabolism, and through the interaction between the lactoferrin and the vomitoxin, the growth of the intestinal villi is promoted, and the absorption capacity of the intestinal tract to nutrients is strengthened.

The invention discloses a preparation method and application of a sodium alginate microcapsule loaded with a curcumin-spirulina composite drug and piperine, and belongs to the technical field of pharmaceutical preparations. In the system, curcumin is loaded on spirulina through electrostatic force, and curcumin and piperine are jointly encapsulated in a sodium alginate gel microcapsule through a microfluidic system. The gel microcapsule system has an ileum targeting function, and can effectively protect the encapsulated composite drug from being eroded by gastric acid. After entering the small intestine, the system can realize step-by-step release of the drug; piperine in the gel is firstly released to inhibit the efflux effect of p-gp protein, and the curcumin-spirulina composite drug resides between small intestine villi and is slowly released. The characteristic of step-by-step release can effectively promote the absorption and utilization of curcumin, amplify the anti-oxidation and immune regulation ability of curcumin at the ileum part, and promote the repair of irradiation enteritis. The system has good biocompatibility, is low in cost and simple to manufacture, and has a wide prospect in the aspect of prevention and treatment of irradiation enteritis.

The invention provides application of C. sporogenes or supernate thereof in preparation of a medicine for preventing and / or treating Graves disease, and belongs to the technical field of biological medicine. The research finds that after intervention of C.sporogenes and supernate thereof, thyroid hormones FT4 and TRAb of a mouse suffering from Graves disease are obviously reduced, TSH is increased, serum inflammation anti-inflammatory factors are increased, proinflammatory factors are reduced, body weight is increased, and food intake is reduced; the colon tissue structure is complete, columnar epithelial cells of the epithelial layer are arranged in order, cup-shaped cells are evenly distributed and moderate in number, colon villus is complete, a small amount of panesian cells can be seen in crypts, thyroid tissue follicles are normal in structure and are oval or round, the follicles are different in size, the epithelial cells are in a single-layer flat shape and are arranged in order, and the follicles contain rich colloid. The Graves disease can be effectively treated.

The invention discloses application of tussilagone in preparation of a medicine for resisting radiation injury, and belongs to the technical field of biology. The technical problem to be solved by the invention is how to resist radiation damage. The application provided by the invention specifically refers to application of tussilagone in preparation of a product for treating or / and relieving body injury caused by radiation. Experiments prove that tussilagone can effectively relieve hyperemia and bleeding and inflammatory cell infiltration of pulmonary alveoli of mice after radiation; the hepatic cord structure damage and hepatic sinus hyperemia in the hepatic tissue are relieved; disorder and vacuolation of a bone marrow structure can be relieved, and recovery of hematopoietic cells in bone marrow is promoted; edema and shedding of intestinal villi can be relieved, and the integrity of the intestinal structure can be partially repaired; and hair follicle structure damage and fiber bundle hyperplasia in skin tissues are improved.

The invention belongs to the technical field of animal medicine, and discloses a pharmaceutical composition for preventing or treating porcine epidemic diarrhea. The paeoniflorin extract, the pawpaw total triterpenes, the mesalazine, the honeysuckle flower water extract and the mannan oligosaccharide are scientifically compounded, so that multi-target synergistic treatment is realized. Mesalazine can inhibit intestinal inflammation, and pawpaw total triterpenes can relieve oxidative damage and protect intestinal epithelium; the honeysuckle water extract is used for blocking virus infection, and the paeoniflorin extract is used for repairing intestinal villi; and the mannan oligosaccharide can regulate intestinal flora. All the components have a synergistic effect, the porcine epidemic diarrhea symptom is effectively controlled, the intestinal function is repaired, the cad pig incidence rate is reduced, and compared with a traditional scheme, pig herd health and breeding benefits can be more efficiently guaranteed.